HC Wainwright Predicts Evolus’ FY2029 Earnings (NASDAQ:EOLS)

Evolus, Inc. (NASDAQ:EOLS) – Equities research analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Evolus in a research note issued on Wednesday, January 22nd. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of $4.43 for the year. HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.63) per share.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Evolus in a research note on Tuesday.

Evolus Trading Down 1.0 %

Shares of Evolus stock traded down $0.14 during midday trading on Thursday, reaching $13.99. 63,950 shares of the company’s stock traded hands, compared to its average volume of 927,781. The stock has a 50 day moving average of $11.70 and a 200-day moving average of $13.75. Evolus has a 12 month low of $9.25 and a 12 month high of $17.82. The company has a market cap of $885.91 million, a PE ratio of -15.40 and a beta of 1.32. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. KBC Group NV purchased a new stake in shares of Evolus during the fourth quarter valued at approximately $49,000. Quarry LP purchased a new stake in Evolus during the 2nd quarter valued at $54,000. Point72 Asset Management L.P. bought a new stake in shares of Evolus in the 3rd quarter worth $132,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Evolus in the third quarter worth $191,000. Finally, Profund Advisors LLC purchased a new stake in shares of Evolus during the second quarter valued at $130,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.